Form 4: Entera Bio Director Gerald M. Ostrov Acquires Shares and Options in Lieu of Fees

Director Gerald M. Ostrov of Entera Bio Ltd. received shares and stock options as compensation for board service and an annual grant.

Summary

• Gerald M. Ostrov, a director at Entera Bio Ltd., acquired 8,038 ordinary shares on January 15, 2025, as compensation for his services as a director for the fourth quarter of 2024.
• These shares were awarded in lieu of cash fees.
• On the same date, Mr. Ostrov also received 28,509 stock options as part of the board's annual grant to directors.
• These options have an exercise price of $2.28 and vest quarterly over a one-year period starting January 1, 2025.
• Following these transactions, Mr. Ostrov directly owns 46,936 ordinary shares and 28,509 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard director compensation practices, which is generally positive for alignment of interests. There are no negative implications.

Positives

• The award of shares and options to a director demonstrates the company's commitment to aligning director interests with shareholder value.
• The vesting schedule of the options encourages long-term commitment from the director.

Management Comments

• The Board of Directors awarded shares to the Reporting Person in lieu of cash fees for services rendered as a director for the fourth quarter of 2024.
• The options represent the Board's annual grant of options to directors of the Company.

Industry Context

It is common practice for companies to compensate directors with a mix of cash, shares, and stock options to align their interests with the company's long-term performance.

Comparison to Industry Standards

• Many biotech companies use stock options as part of director compensation packages.
• The vesting schedule of one year is a common practice to ensure directors are incentivized to stay with the company.
• The exercise price of $2.28 is specific to Entera Bio and would need to be compared to other similar companies to assess if it is in line with industry standards.

Stakeholder Impact

• Shareholders may view the director's increased stake in the company as a positive sign of alignment.
• The vesting schedule of the options may encourage long-term commitment from the director.

Key Dates

Keywords

Entera Bio, Director Compensation, Stock Options, Share Acquisition, Form 4, Gerald M. Ostrov, Director Grant